GlassScriptPhysician profile
Amy D Lazar
NPI 1568441988
$2,905.50
in general payments reported to CMS, 2019-2025
28 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $136 · 2021: $59.33 · 2022: $247 · 2023: $550 · 2024: $585 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.95 |
| Education | $171.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $641.06 | 2019-2025 | |
| Aerin Medical INC. | $387.32 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $336.14 | 2019-2025 | Dupixent |
| Optinose US, INC. | $250.56 | 2019-2024 | |
| Glaxosmithkline, LLC. | $226.33 | 2019-2025 | Nucala, Arexvy |
| Stryker Corporation | $146.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $137.98 | 2023-2025 | |
| Medtronic, INC. | $107.22 | 2021-2025 | Propel, Stealthstation S8 Platform |
| Takeda Pharmaceuticals U.S.A., INC. | $103.98 | 2019-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $75.21 | 2019-2023 | |
| Csl Behring | $68.64 | 2019-2025 | Hizentra |
| Amgen INC. | $65.94 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $45.12 | 2022-2025 | Odactra, Ragwitek, Grastek |
| Grifols USA, LLC | $42.85 | 2025 | Xembify |
| Lilly USA, LLC | $42.26 | 2024-2025 | Ebglyss |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $33.89 | 2019 | |
| Incyte Corporation | $29.36 | 2024 | Opzelura |
| Smith+Nephew, INC. | $21.05 | 2019 | |
| Acadia Pharmaceuticals INC | $20.89 | 2025 | Nuplazid |
| Mimedx Group, INC. | $18.69 | 2025 | |
| Acclarent, INC | $17.78 | 2019 | |
| Hikma Pharmaceuticals USA | $15.55 | 2022 | |
| Shire North American Group INC | $13.77 | 2019 | |
| Kaleo, INC. | $12.85 | 2020 | |
| Olympus America INC. | $12.72 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.14 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.04 | 2020 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.